An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/20/2018 |
| Start Date: | January 19, 2018 |
| End Date: | January 1, 2020 |
| Contact: | Jessica Sollars, RN |
| Email: | jlsherma@iupui.edu |
| Phone: | 317-278-5117 |
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment
of triple negative breast cancer
of triple negative breast cancer
Inclusion Criteria:
- Metastatic Triple-negative Breast Cancer
- Willingness to undergo tumor biopsy
- Patients must have received at least 1 prior chemotherapy regimen for metastatic
disease
Exclusion Criteria:
- Previous treatment with mTOR inhibitor
- Untreated brain metastases
We found this trial at
1
site
Click here to add this to my saved trials
